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Abstract
Background: Serum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients 
compared to healthy donors, suggesting its potential utility for early diagnosis. Therefore we aimed to estimate the 
utility of the sCD26 as a biomarker for CRC and advanced adenomas in a high-risk group of patients. The relationship of 
this molecule with polyp characteristics was also addressed.
Methods: sCD26 levels were measured by ELISA in 299 symptomatic and asymptomatic patients who had undergone 
a colonoscopy. Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel 
disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC.
Results: At a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% 
(95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology. Clinicopathological analysis of polyps 
showed a relationship between the sCD26 and the grade of dysplasia and the presence of advanced adenomas. 
Hence, a 58.0% (95% CI, 46.5-68.9%) sensitivity detecting CRC and advanced adenomas was obtained, with a specificity 
of 75.5% (95% CI, 68.5-81.0%).
Conclusions: Our preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive 
assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening 
of CRC and advanced adenomas. Additional comparative studies in average-risk populations are necessary.
Background
Colorectal cancer (CRC) is one of the four most prevalent
cancers in Western countries due to a low recovery rate
in advanced stages, when micrometastases may be
already present. It develops from precancerous lesions
( a de nom as)  t ha t  a r e  eas ily  r e m oved by po lypect om y ,  a
procedure that reduces CRC incidence by 75-90% [1];
moreover, treatment of early diagnosed tumours has a
good prognosis [2]. Furthermore, according to the MIS-
CAN-COLON simulation model, a 23% reduction in
CRC mortality would be achieved with the screening of at
least 70% of the target population [3]. Therefore screen-
ing for CRC aims to reduce mortality rates by detection
and removal of early-stage tumours, and incidence rates
by identification and resection of polyps [4].
There is a great variety of methods for the detection of
CRC. A review of the ongoing screening initiatives world-
wide was recently published [5]. The latest Joint Colorec-
tal Cancer Screening Guidelines [6] divide the available
tests into two categories: those primarily aimed to detect
cancer (blood and DNA stool tests), and those directed to
detect also advanced lesions (endoscopic and radio-
graphic methods).
Within the available invasive tests are the flexible sig-
moidoscopy, the double-contrast barium enema and the
colonoscopy. The latter is recommended nowadays as the
gold standard, though its miss rates have been estimated
as 22% for adenomas and 2-6% for CRC [7]. However,
bowel preparation constitutes the most objectionable
aspect of the procedure, fundamental for a proper
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screening colonoscopy [8]. Other limitations of the
colonoscopy are the risk of complications, the costs, and
access. Regarding non-invasive tests, the most common
method, nowadays recommended for CRC screening, is
the guaiac faecal occult blood test (gFOBT), with highly
variable and brand-dependent sensitivities and specifici-
ties [6,9] and requiring dietary restrictions.
Thus there is an imperative need for developing non-
invasive screening tests for the detection of CRC and ade-
nomas, and hence many current studies are evaluating
serum markers. Examples of these are the α-defensins
[10], the nicotinamide N-methyltransferase [11], the α-L-
fucosidase [12], or the colon cancer-specific antigens
(CCSA) -2, -3 and -4 [13,14]. A major drawback in these
studies is they are limited to discriminating between CRC
patients and healthy individuals, leaving aside precursor
lesions and not including in the control cohort individu-
als with benign pathologies.
Previous studies of our group detected that soluble
serum CD26 (sCD26) levels were diminished in CRC
patients as compared to healthy donors [15,16]. In those
studies, a sCD26 cut-off of 410 ng/mL demonstrated a
90% diagnostic efficiency, with a specificity and sensitiv-
ity of 90% as well [15]. This high diagnostic efficiency,
even in early tumour stages, suggested its potential utility
for diagnosis. Thus we considered of interest to extend
the validation of the sCD26 as an early biomarker for
CRC, including also precancerous lesions (adenomas).
One of the novelties of the study is the use of a colono-
scopically healthy cohort instead of a blood donor cohort
as the control population. Moreover, this is the first time
the sCD26 is analyzed regarding the clinicopathological
characteristics of colorectal polyps. Thus, we aim to anal-
yse the relationship of the serum CD26 levels with the
colonoscopic findings, in order to validate the utility of
this protein as a marker for CRC diagnosis.
Methods
Population
The population studied consisted of patients from the
CHUVI hospital (Complejo Hospitalario Universitario de
Vigo; Spain) who had undergone colonoscopy at the Gas-
troenterology Department. All the procedures described
were performed according to the clinical ethical practices
of the Spanish Government. The study was approved by
the Galician Ethical Committee for Clinical Research
(2002/059) and complied with the tenets of the Helsinki
Declaration, the Oviedo Agreement, the Organic Law for
Data Protection 15/1999 and the Royal Decree 1720/
2007. Anonymity was warranted through the use of clini-
cal history numbers. For patients willing to be included in
the study, informed consent was obtained and blood was
extracted. The only exclusion criterion was a non-com-
pleted colonoscopy (understood as completed when the
caecum was reached). The 299 patients included were
both males and females, with ages ranging from 18 to 93
years. Clinical histories were recorded, including symp-
toms of bowel disease, personal history of polyps, CRC
and other cancers, family history of cancer, and colonos-
copy indication. This was mostly due to symptoms as rec-
tal bleeding (35.5%), abdominal pain (10%), diarrhoea
(9%), constipation (5.7%), anaemia (5%), but also for col-
orectal polyp (12.7%) or cancer (4.3%) surveillance, or
CRC screening (12.4%). All procedures were blinded.
Based on the histological report, patients were classi-
fied into: no colorectal pathology, non-inflammatory
bowel disease (non-IBD), inflammatory bowel disease
( I B D ) ,  p o l y p s  a n d  C R C ;  p o l y p s  w e r e  s u b - c l a s s i f i e d  a s
hyperplastic or adenomas. Advanced adenomas were
defined as those larger than 10 mm, with tubulovillous or
villous histology, or with high-grade dysplasia. Patients
with more than one polyp were classified according to the
most advanced lesion. CRC patients were classified
according to Dukes' staging. No carcinomas in situ were
detected in the patients included in the study.
Collection of blood samples and determination of the 
sCD26 levels
Blood samples were collected, coagulated at room tem-
perature for 20 min, and centrifuged at 2,000 g 15 min.
Sera were stored at -80°C. The sCD26 concentration was
measured with the sCD26 ELISA kit (Bender Medsys-
tems; Vienna, Austria) according to the manufacturer's
instructions. Colorimetric quantification was performed
with a microplate reader (model 550; Bio-Rad, USA) at
450/570 nm.
Statistical analysis
Statistical analyses were performed with the SPSS pack-
age (v16.0); tests were two-sided; p-values < 0.05 were
considered significant. Normal distributions and homo-
geneity of variances were verified by Kolmogorov-
Smirnov and Levene';s tests, respectively. Analysis of two
independent samples was done by Mann-Whitney's U,
whereas for more samples we employed the Kruskal-Wal-
lis test. Chi-square or Fischer's exact tests were done with
contingency tables, and applied for analyses regarding
positivity/negativity of the sCD26. Bonferroni, false dis-
covery rate (FDR) and SGoF tests were subsequently per-
formed with the SGoF metatest software to correct for
multiple comparison [17]. The sCD26 ability to separate
healthy from diseased patients was studied by receiver
operating characteristic (ROC) curves. Sensitivity and
specificity were calculated using MedCalc (v.10.0.2).De Chiara et al. BMC Cancer 2010, 10:333
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Results
sCD26 levels according to the colonoscopic results
According to the colonoscopic diagnosis, the 299 patients
were classified as 68 patients with no colorectal pathol-
ogy (symptomatic with rectal bleeding, abdominal pain,
diarrhoea, anaemia, constipation, or asymptomatic with
personal history of polyps or CRC, and family history of
polyps); 64 patients with non-IBD (haemorrhoids and
diverticula); 26 patients with IBD (colitis or Crohn's dis-
ease); 108 patients with colorectal polyps (hyperplastic
polyps, non-advanced adenomas and advanced ade-
nomas); and 33 patients with CRC.
As shown in table 1, the average sCD26 level for the 6
groups with no colorectal pathology was 641.2 ± 241.2
ng/mL; individuals with anaemia showed a considerably
low sCD26 mean (370.8 ± 144.7 ng/mL), statistically dif-
ferent from other non-colorectal pathology patients (U
test p = 0.001). Regarding patients with colorectal pathol-
ogy, the non-IBD group exhibited mean sCD26 levels
similar to the non-colorectal pathology group (612.2 ±
231.0 ng/mL). In contrast, patients with IBD showed
lower values with relatively more variation (434.4 ± 239.7
ng/mL). Patients diagnosed as having polyps (both hyper-
plastic and adenomas) resulted in an intermediate mean
sCD26 concentration (588.0 ± 246.5 ng/mL), while
patients with CRC registered the lowest levels (403.7 ±
278.2 ng/mL).
The Kolmogorov-Smirnov test demonstrated, except
for the CRC population (p = 0.035), a normal distribution
of the sCD26 concentration for all the groups. When the
levels of sCD26 were compared among all the five groups
of patients, we found significant differences (Kruskal-
Wallis test p < 0.001). Moreover, this differences were not
related to gender (U test p = 0.219) or age (≤ 50 years or >
50 years; U test p = 0.109), as reported in a large cohort
study [18].
ROC curve and sCD26 positivity
To evaluate the utility of the sCD26 as a tumour marker,
we estimated a cut-off to differentiate the CRC group (33
patients) from the control population (68 patients with
no colorectal pathology). First we constructed the ROC
curve, which resulted in an area of 0.811 (95% CI, 0.721-
0.882; p < 0.0001). On the basis of this plot, table 2 shows
four different potential cut-off values with their respec-
tive sensitivity and specificity. Sensitivity for CRC almost
reached 85% at the cut-off of 500 ng/mL, but with a spec-
ificity below 75%; when specificity was raised up to 83.8%
at 390 ng/mL, sensitivity resulted in a 57.6%. The cut-off
value with the highest average diagnostic performance
was 460 ng/mL, showing a sensitivity of 81.8% (95% CI,
64.5-93.0%) with a specificity of 79.4% (95% CI, 67.9-
88.3%).
A positive sCD26 value was therefore ≤ 460 ng/mL (fig-
ure 1). The positivity rate increased from 20.6% (14/68) in
the non-colorectal pathology group to 81.8% (27/33) in
the CRC group. Patients with non-IBD, IBD, hyperplastic
polyps, non-advanced adenomas and advanced ade-
nomas showed intermediate rates, corresponding to
28.1% (18/64), 69.2% (18/26), 22.2% (4/18), 22.5% (9/40)
and 41.7% (20/48), respectively.
Relationship between the sCD26 and the 
clinicopathological features of polyps
We analysed the relationship of the sCD26 with the histo-
pathological characteristics of the colorectal polyps
found by colonoscopy (table 3), including: number of pol-
yps (1-2, 3 or more); size (≤ 0.5 cm, 0.6-1 cm, > 1 cm);
location (rectum, sigma, left colon, transverse colon, right
colon); morphology (sessile, pediculated, flat); histology
(hyperplasic, adenoma) and detailed histology (hyper-
plastic, tubular, villous, tubulovillous); grade of dysplasia
(absence, low-grade, high-grade); and presence of
advanced adenomas. The histology for two polyps was
missing. The variables gender and age (≤ 50 and >50
years) were also studied, confirming no statistical differ-
ences in relation to the sCD26 positivity (p = 0.212 and p
= 0.132, respectively).
The Chi-square tests revealed no statistical differences
regarding the number of polyps, their size, location, mor-
phology or histology. Differences close to significant were
observed between the sCD26 positivity and the grade of
dysplasia (p = 0.056). The positivity rate increased gradu-
ally while the degree of dysplasia became more severe:
22.2% for non-dysplastic polyps, 32.5% for low-grade dys-
plastic adenomas and almost double (60.0%) for high-
grade dysplastic adenomas. When comparing the sCD26
positivity rate of the advanced and non-advanced ade-
nomas populations, statistically significant differences
were detected (p  = 0.048). Bonferroni, FDR and SGoF
post-hoc tests were not significant for any of these analy-
ses.
Finally, diagnostic parameters were calculated for the
detection of advanced adenomas and CRC, with the con-
trol group including all the remaining cohorts (table 4).
At the 460 ng/mL cut-off, sensitivity resulted in 58.0%
(95% CI, 46.5-68.9%), with a specificity of 75.5% (95% CI,
68.5-81.0%). When these parameters were calculated for
the detection of only CRC patients, the sensitivity
increased to 81.8% (95% CI, 64.5-93.0%) whereas the
specificity was just slightly diminished to 72.3% (95% CI,
65.0-77.2%). This value increased to 90% (95% CI, 73.4-
97.8%) if the specificity was calculated for the non-symp-
tomatic group versus the CRC group.
Discussion
The glycoprotein CD26 or dipeptidyl peptidase IV
(DPPIV, E.C. 3.4.14.5) is an exopeptidase of the plasma
membrane able to release dipeptides from the N-terminal
end of peptides/proteins bearing proline or alanine in theDe Chiara et al. BMC Cancer 2010, 10:333
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penultimate position [19]. Biological fluids contain rela-
tively high levels of sCD26, which is presumably shed by
proteolytic cleavage from any cell expressing transmem-
brane CD26 [20]. Although its origin is still unclear, the
liver and the T cells are cited as the most likely sources
[21].
The measurement of the sCD26 levels was performed
in serum from individuals whom, due to different medical
indications, had undergone colonoscopy; most of them
referred abdominal, colon or rectal symptoms, or famil-
ial/personal history of polyps or CCR. The individuals
without colorectal findings after the colonoscopy were
considered as the control cohort; the remaining were
c l a s s i f i e d  a s :  n o n - I B D ,  I B D ,  c o l o r e c t a l  p o l y p s  o r  C R C
patients. The mean sCD26 concentration decreased,
although non-significantly, as the pathology diagnosed
Table 1: Average sCD26 concentration for the groups studied according to the colonoscopy result.
No colorectal 
pathology
Clinical condition n Mean ± 
SD sCD26 (ng/mL)
Rectal bleeding 8 651.5 ± 190.2
Abdominal pain 10 586.1 ± 194.4
Diarrhoea 9 649.5 ± 306.8
641.2 ± 241.2
Anaemia 7 370.8 ± 144.7
Constipation 4 782.7 ± 194.6
No symptoms* 30 698.5 ± 234.2
Colorectal 
pathology
Diagnosis n Mean ± SD
sCD26 (ng/mL)
Non-inflammatory Haemorrhoids 36 655.3 ± 240.4
bowel disease 612.2 ± 231.0
(non-IBD) Diverticula 28 556.7 ± 209.6
Inflammatory  Colitis 20 413.2 ± 195.5
bowel disease 434.4 ± 239.7
(IBD) Crohn's disease 6 505.1 ± 355.8
Hyperplastic polyps 18 560.4 ± 201.3
Polyps Non-advanced adenomas 40 611.1 ± 263.8 588.0 ± 246.5
Advanced adenomas 48 566.7 ± 225.8
Duke's A 2 513.9 ± 240.4
Duke's B 12 369.8 ± 147.4
CRC 403.7 ± 278.2
Duke's C 15 402.0 ± 360.3
Duke's D 4 457.0 ± 323.0
SD: standard deviation of the mean; *: personal history of polyps or CRC, or familial history of CRC.De Chiara et al. BMC Cancer 2010, 10:333
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was more severe (as seen in table 1), this is, from no col-
orectal pathology to CRC, with a noticeable decrease in
the group with IBD.
In our previous study, the control cohort was formed
exclusively by healthy donors [15], whereas in the present
study it was formed by individuals with confirmed no col-
orectal pathology but bearing symptoms, or with history
of polyps or cancer. Thus we calculated a new cut-off of
460 ng/mL, higher than the value of 410 ng/mL reported
for healthy donors [15].
According to this cut-off, within the no colorectal
pathology group, individuals with anaemia showed a sub-
stantially elevated positivity rate (71.4%) as expected
from their mean levels. Non-IBD exhibited a low positiv-
ity rate (28.1%), whereas the IBD group reached 73.1%.
This pathology is associated with at least a 5-fold
increased risk for CRC, representing one of the highest
risk groups based on the inflammation-dysplasia-carci-
noma sequence [22]. In compliance with this sequence,
the sCD26 positivity rate increased from no colorectal
pathology to hyperplastic polyps and non-advanced ade-
nomas, with a further increase in advanced adenomas
and CRC.
The capability of colorectal polyps to develop into can-
cer is related to the size of the lesion, the proportion of
villous component and the grade of dysplasia. In relation
to dysplasia, a morphological marker of neoplastic
lesions, we observed a direct (positive) trend between the
grade of dysplasia and the positivity of the biomarker,
though there was no significant correlation between both
parameters. Concerning advanced adenomas, a term
commonly used to group adenomas that have an
increased likelihood of malignant transformation, the
sCD26 positivity resulted statistically significant.
Recent works also studied other potential markers in
relation to polyp characteristics: for the serum sulfatase
activity, differences regarding the number of adenomas
(single or multiple) were significant [23]; serum leptin,
adiponectin and resistin also differed between controls
and patients with adenomas or CRC, though there was no
relationship with dysplasia, histopathology or polyp
localization [24].
Table 2: Sensitivity and specificity of the sCD26 at different cut-off values for separating individuals with no colorectal 
pathology from those with CRC.
Cut-off (ng/mL) Sensitivity (95% CI) Specificity (95% CI) +LR -LR
390 57.6% (38.2-74.5) 83.8% (72.9-91.6) 3.6 0.5
410 72.7% (54.5-86.7) 80.9% (69.5-89.4) 3.8 0.3
460 81.8% (64.5-93.0) 79.4% (67.9-88.3) 4.0 0.2
500 84.9% (68.1-94.8) 72.1% (59.9-82.3) 3.0 0.2
+LR: Positive likelihood ratio; -LR: Negative likelihood ratio.
Figure 1 Dot plot representing the sCD26 concentration according to the colonoscopic diagnosis. Horizontal line: 460 ng/mL cut-off. 1: No col-
orectal findings (n = 68); 2: non-IBD (n = 64); 3: IBD (n = 26); 4: hyperplastic polyps (n = 18); 5: non-advanced adenomas (n = 40); 6: advanced adenomas 
(n = 48); 7: CRC (n = 33).De Chiara et al. BMC Cancer 2010, 10:333
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Table 3: Chi-square and Fischer's exact analyses for the clinicopathological characteristics of polyps in relation to the 
sCD26 positivity
Variable Mean ± SD nsCD26+/nt sCD26+ rate p
sCD26 (ng/mL)
Number
1-2 577.6 ± 244.3 28/84 33.3 0.807
3 or more 624.6 ± 256.1 7/24 29.2
Size
≤ 0.5 cm 525.2 ± 208.1 11/32 34.4
0.6 - 1 cm 673.9 ± 298.7 6/28 21.4 0.339
> 1 cm 579.9 ± 226.7 18/48 37.5
Location
rectum 549.0 ± 190.0 7/24 29.2
sigma 617.1 ± 273.7 13/44 29.5
left colon 571.7 ± 194.5 7/21 33.3 0.475
transverse colon 427.0 ± 157.6 4/6 66.7
right colon 662.4 ± 324.5 4/13 30.8
Morphology
sessile 592.8 ± 264.4 18/64 28.1
pediculated 585.3 ± 230.9 15/39 38.5 0.517
flat 548.6 ± 126.5 2/5 40.0
Histology
hyperplastic 560.4 ± 201.3 4/18 22.2 0.413
adenomas 597.2 ± 256.1 30/88 34.1
Detailed histology
hyperplastic 560.4 ± 201.3 4/18 22.2
tubular 605.3 ± 259.9 24/72 33.3 0.358
villous 612.6 ± 305.8 2/6 33.3
tubulovillous 529.7 ± 207.5 4/10 40.0
Dysplasia
no dysplasia 560.4 ± 201.3 4/18 22.2
low-grade 
dysplasia
598.7 ± 250.5 27/83 32.5 0.056
high-grade 
dysplasia
562.9 ± 293.1 3/5 60.0
Adenomas
non-advanced 633.9 ± 286.9 9/40 22.5 0.048*
advanced 566.7 ± 225.8 20/48 41.7
SD: standard deviation; nsCD26+: number of individuals with sCD26 levels ≤ 460 ng/mL; nt: total number of individuals per group; sCD26+ 
rate: sCD26 positivity rate.De Chiara et al. BMC Cancer 2010, 10:333
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In our experimental setting we have also evaluated the
diagnostic parameters for the sCD26. At the 460 ng/mL
cut-off, the sensitivity and specificity for CRC versus non-
cancer groups were 81.8% and 72.3%, respectively. This
specificity is measured in the framework of symptomatic
and asymptomatic patients bearing intermediate benign
pathologies including non-IBD and IBD as well as polyps.
When considering only asymptomatic individuals speci-
ficity increases to 90%, which agrees with the results pre-
viously published by our group [15]; nevertheless a
decrease in sensitivity will be expected in this context.
In an asymptomatic high-risk cohort of individuals
with familial history of CRC or personal history of CRC
or adenoma, Hazazi et al. [25] suggested the use of a
quantitative immunochemical FOBT (iFOBT) for screen-
ing of high-risk individuals. Excluding individuals with
anaemia, rectal bleeding and IBD, they reported a sensi-
tivity and specificity for CRC of 100% and 85.3%, respec-
tively.
In the classical CRC screening studies in average-risk
individuals, the gFOBT (guaiac-based) is extensively
used, despite its wide range of sensitivity and specificity.
The most common tests are the Hemoccult II® (rehy-
drated or unrehydrated) and the Hemoccult SENSA®,
though the unrehydrated gFOBT is the one recom-
mended for screening [26]. For the unrehydrated Hemoc-
cult II®, the most accurate diagnostic parameters have
been estimated with one-time testing on a Chinese [27]
and an American populations [28]; in both, colonoscopy
was performed to all individuals with positive or negative
gFOBT results, reporting a sensitivity for CRC of 25 and
12.9%, and a specificity of 80 and 95.2%, respectively
[27,28]. These studies reflect a poor sensitivity, although
it is slightly improved with repeated annual or biennial
testing (54-80%), reaching up to 97.7% specificity [29,30].
On the other hand, a 50% sensitivity was obtained for a
one-time rehydrated testing combined with sigmoidos-
copy, though no specificity was reported, perhaps owing
to an increase in the number of false positives due to
rehydration [31].
When a highly sensitive test like the Hemoccult
SENSA® is used, a 71-79% sensitivity is reached with sin-
gle testing, and about 85% with multiple testing, with cor-
responding specificities of 86% and 95% [32,33].
However, these parameters are probably overestimated as
these studies lacked colonoscopic examination of the
negative cases.
Besides guaic-based FOBT, iFOBT has been recently
offered as an alternative for average-risk screening. The
studies reported up to date have shown that the iFOBT is
more adequate for screening because of its high specific-
ity since it detects human globin [26].
Throughout our study, evidence was gathered regard-
ing the utility of the sCD26 in the detection of advanced
Table 4: Sensitivity and specificity for the sCD26 at the cut-off value of 460 ng/mL
Cohort nsCD26+/nt Sensitivity (95% CI)
CRC 27/33 81.8% (64.5-93.0)
Advanced adenomas 20/48 41.7% (27.6-56.8)
CRC and advanced adenomas 47/81 58.0% (46.5-68.9)
Non-advanced adenomas and advanced adenomas 30/88 34.1% (24.3-45.0)
Cohort nsCD26-/nt Specificity (95% CI)
No colorectal findings-no symptoms 27/30 90.0% (73.4-97.8)
No colorectal findings 54/68 79.4% (67.9-88.3)
No colorectal findings, non-IBD, IBD, hyperplastic polyps, non-advanced and advanced 
adenomas
191/264 72.3% (65.0-77.2)
No colorectal findings, non-IBD, IBD, hyperplastic polyps and non-advanced adenomas 163/216 75.5% (68.5-81.0)
nsCD26+: number of individuals with sCD26 levels ≤ 460 ng/mL; nsCD26-: number of individuals with sCD26 levels > 460 ng/mL; nt: total 
number of individuals per group.De Chiara et al. BMC Cancer 2010, 10:333
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adenomas. In separating CRC and advanced adenomas
from all other groups, the sCD26 exhibited a 58.0% sensi-
tivity and a 75.5% specificity. For the same pathologies
(CRC and advanced adenomas) in an asymptomatic high-
risk cohort, Hazazi et al. [25] reported for a quantitative
iFOBT a sensitivity and specificity of 65.3% and 87.5%,
respectively.
Regarding studies performed in average-risk individu-
als for the detection of CRC and advanced adenomas,
gFOBT has shown a sensitivity of 10.8-14.3% [27,28] and
a specificity of 79.2% [27], and consequently is not rec-
ommended for the detection of advanced lesions [4,6].
On the other hand, iFOBT showed a sensitivity of 33.1%
and a specificity of 97.5%, though these parameters were
given for only distal advanced neoplasm as compared to
flexible sigmoidoscopy [25].
In relation to other experimental serum biomarkers for
advanced adenomas, the CCSA-2 has shown a 97.3% sen-
sitivity with a 78.4% specificity considering normal
colonoscopy, hyperplastic polyps and non-advanced ade-
nomas [13], whereas for CCSA-3 and -4 a combined sen-
sitivity of 91.3% and a specificity of 78.7% was reported
[14]. While sCD26 shows lower sensitivity, the specificity
is equivalent even including patients with confounding
pathologies such as IBD, which were not present in other
studies.
Although sCD26 seems to perform adequately as a
blood biomarker for CRC and advanced adenomas, inde-
pendent of the frequent but intermittent bleeding unlike
gFOBT or iFOBT, our study presents some limitations
that should be considered: i) the symptomatic population
included is at high-risk for CRC, with an elevated preva-
lence of colorectal pathology; ii) although no differences
regarding age were detected, the age range of the patients
differs from that recommended for screening; iii) the
classification of the patients into the categories proposed
resulted in several sub-groups with a small number of
patients. Therefore, further research in a large population
and under a screening context is desirable, along with the
comparison to a sensitive gFOBT or iFOBT, and other
experimental non-invasive methods.
Conclusions
Our results show that measurement of the sCD26 is a
non-invasive and reasonably sensitive assay, which could
be combined with others such as the faecal occult blood
test, for the early diagnosis and screening of CRC and
advanced adenomas. With this aim, we are currently ini-
tiating a multicentric, prospective, double-blinded study
in an average-risk population, where the performance of
the quantitive iFOBT and the sCD26 assay will be
assessed and compared regarding the gold standard
colonoscopy.
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